Skip to main content
SpringerLink
Log in

Therapie von chronischem Pruritus – was ist neu?

Treatment of chronic pruritus—what is new?

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Chronischer Pruritus gehört zu den häufigsten und sehr belastenden Symptomen in der Medizin. Die Therapie bleibt eine große Herausforderung, da es kaum zugelassene Therapien gibt. In der jüngsten Vergangenheit ermöglichte ein besseres Verständnis der Pathogenese, die Ergebnisse in neue Therapieformen umzusetzen. Die verschiedenen Therapien zielen auf eine Vielzahl von Punkten in der Prurituskaskade ab – von der Blockade intrazellulärer und interzellulärer Signalwege in der Haut bis zur Modulation der Neurotransmission. Dieser Beitrag gibt einen Überblick über die aktuellen Therapieoptionen, basierend auf der aktuellen S2K-Leitlinie, und über die jüngste Entwicklung der antipruritischen Therapien.

Abstract

Chronic pruritus is one of the most common and stressful symptoms in medicine. Therapy remains a great challenge because of the lack of approved therapies. In the recent past a greater understanding of the pathogenesis has enabled the results to be translated into new forms of therapy. The various therapies target a wide range of points in the pruritic cascade—from blockade of intracellular and intercellular signaling pathways in the skin to the modulation of neurotransmission. This article provides a summary of current therapeutic options based on the current S2K guideline and gives an overview about recent developments in antipruritic treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Beck LA, Thaçi D, Hamilton JD et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371(2):130–139

    Article  PubMed  CAS  Google Scholar 

  2. Beuers U, Kremer AE, Bolier R et al (2014) Pruritus in cholestasis. Facts and fiction. Hepatology 60(1):399–407

    Article  PubMed  CAS  Google Scholar 

  3. Bissonnette R, Papp KA, Poulin Y et al (2016) Topical tofacitinib for atopic dermatitis. A phase IIa randomized trial. Br J Dermatol 175(5):902–911

    Article  PubMed  CAS  Google Scholar 

  4. Cowan A, Kehner GB, Inan S (2015) Targeting itch with ligands selective for κ opioid receptors. Handb Exp Pharmacol 226:291–314

    Article  PubMed  CAS  Google Scholar 

  5. Dubertret L, Mrowietz U, Ranki A et al (2006) European patient perspectives on the impact of psoriasis. The EUROPSO patient membership survey. Br J Dermatol 155(4):729–736

    Article  PubMed  CAS  Google Scholar 

  6. Feldman SR, Thaçi D, Gooderham M et al (2016) Tofacitinib improves pruritus and health-related quality of life up to 52 weeks. Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 75(6):1162–1170.e3

    Article  PubMed  CAS  Google Scholar 

  7. Gordon KB, Duffin KC, Bissonnette R et al (2015) A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 373(2):136–144

    Article  PubMed  CAS  Google Scholar 

  8. Gordon KB, Colombel J‑F, Hardin DS (2016) Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 375(21):2102. https://doi.org/10.1056/NEJMc1610828

    Article  PubMed  Google Scholar 

  9. Hawi A, Alcorn H, Berg J et al (2015) Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol 16:47

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Hay RJ, Johns NE, Williams HC et al (2014) The global burden of skin disease in 2010. An analysis of the prevalence and impact of skin conditions. J Invest Dermatol 134(6):1527–1534

    Article  PubMed  CAS  Google Scholar 

  11. Hegade VS, Kendrick SFW, Dobbins RL et al (2016) BAT117213. Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMC Gastroenterol 16(1):71

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Inui S (2015) Nalfurafine hydrochloride to treat pruritus. A review. Clin Cosmet Investig Dermatol 8:249–255

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Kimball AB, Luger T, Gottlieb A et al (2018) Long-term impact of Ixekizumab on psoriasis itch severity. Results from a phase III clinical trial and long-term extension. Acta Derm Venereol 98(1):98–102

    Article  PubMed  Google Scholar 

  14. Kuiper EMM, van Erpecum KJ, Beuers U et al (2010) The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus. Results of a double-blind, randomized, placebo-controlled trial. Hepatology 52(4):1334–1340

    Article  PubMed  CAS  Google Scholar 

  15. Langley RG, Elewski BE, Lebwohl M et al (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371(4):326–338

    Article  PubMed  CAS  Google Scholar 

  16. Liu T, Ji R‑R (2013) New insights into the mechanisms of itch. Are pain and itch controlled by distinct mechanisms? Pflugers Arch 465(12):1671–1685

    Article  PubMed  CAS  Google Scholar 

  17. Matterne U, Apfelbacher CJ, Loerbroks A et al (2011) Prevalence, correlates and characteristics of chronic pruritus. A population-based cross-sectional study. Acta Derm Venereol 91(6):674–679

    Article  PubMed  Google Scholar 

  18. Nemoto O, Furue M, Nakagawa H et al (2016) The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol 174(2):296–304

    Article  PubMed  CAS  Google Scholar 

  19. Ohmura T, Hayashi T, Satoh Y et al (2004) Involvement of substance P in scratching behaviour in an atopic dermatitis model. Eur J Pharmacol 491(2–3):191–194

    Article  PubMed  CAS  Google Scholar 

  20. Paller AS, Tom WL, Lebwohl MG et al (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75(3):494–503.e6

    Article  PubMed  CAS  Google Scholar 

  21. Papp KA, Blauvelt A, Kimball AB et al (2018) Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab. Results from the randomized VOYAGE 1 trial. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.14910

    Article  PubMed Central  PubMed  Google Scholar 

  22. Raap U, Wichmann K, Bruder M et al (2008) Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 122(2):421–423

    Article  PubMed  CAS  Google Scholar 

  23. Reich K, Gooderham M, Bewley A et al (2018) Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment. Findings from the LIBERATE study. J Eur Acad Dermatol Venereol 32(3):397–402

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Roblin D, Yosipovitch G, Boyce B et al (2015) Topical TrkA Kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis. Results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol 95(5):542–548

    Article  PubMed  CAS  Google Scholar 

  25. Simpson EL, Akinlade B, Ardeleanu M (2017) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 376(11):1090–1091

    Article  PubMed  Google Scholar 

  26. Ständer S, Schäfer I, Phan NQ et al (2010) Prevalence of chronic pruritus in Germany. Results of a cross-sectional study in a sample working population of 11,730. Dermatology (Basel) 221(3):229–235

    Article  Google Scholar 

  27. Ständer S, Luger TA (2015) NK-1 Antagonists and Itch. Handb Exp Pharmacol 226:237–255

    Article  PubMed  CAS  Google Scholar 

  28. Ständer S, Siepmann D, Herrgott I et al (2010) Targeting the neurokinin receptor 1 with aprepitant. A novel antipruritic strategy. PLoS ONE 5(6):e10968

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Ständer S, Zeidler C, Augustin M et al (2017) S2k Guidelines for the diagnosis and treatment of chronic pruritus—update—short version. J Dtsch Dermatol Ges 15(8):860–872

    PubMed  Google Scholar 

  30. Steinke S, Langenbruch A, Ständer S et al (2014) Therapeutic benefits in atopic dermatitis care from the patients’ perspective. Results of the German national health care study „Atopic Health“. Dermatology (Basel) 228(4):350–359

    Article  Google Scholar 

  31. Steinke S, Bruland P, Blome C et al (2017) Chronic pruritus. Evaluation of patient needs and treatment goals with a special regard to differences according to pruritus classification and sex. Br J Dermatol 176(2):363–370

    Article  PubMed  CAS  Google Scholar 

  32. Takano N, Sakurai T, Kurachi M (2005) Effects of anti-nerve growth factor antibody on symptoms in the NC/Nga mouse, an atopic dermatitis model. J Pharmacol Sci 99(3):277–286

    Article  PubMed  CAS  Google Scholar 

  33. Toyoda M, Nakamura M, Makino T et al (2002) Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 147(1):71–79

    Article  PubMed  CAS  Google Scholar 

  34. Verstovsek S, Passamonti F, Rambaldi A et al (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120(4):513–520

    Article  PubMed  CAS  Google Scholar 

  35. Wikström B, Gellert R, Ladefoged SD et al (2005) Kappa-opioid system in uremic pruritus. Multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 16(12):3742–3747

    Article  PubMed  CAS  Google Scholar 

  36. Yagi M, Tanaka A, Namisaki T et al (2018) Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. J Gastroenterol. https://doi.org/10.1007/s00535-018-1465-z

    Article  PubMed  Google Scholar 

  37. Yosipovitch G, Ständer S, Kerby MB et al (2018) Serlopitant for the treatment of chronic pruritus. Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol 78(5):882–891.e10

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kompetenzzentrum Chronischer Pruritus (KCP) und Klinik für Hautkrankheiten, Universitätsklinikum Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland

    C. Zeidler, S. Steinke & S. Ständer

  2. Klinik für Dermatologie, Venerologie und Allergologie, Charité – Universitätsmedizin Berlin, Berlin, Deutschland

    M. Metz

Authors
  1. C. Zeidler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Metz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Steinke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Ständer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Zeidler.

Ethics declarations

Interessenkonflikt

C. Zeidler, M. Metz, S. Steinke und S. Ständer geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeidler, C., Metz, M., Steinke, S. et al. Therapie von chronischem Pruritus – was ist neu?. Hautarzt 69, 641–646 (2018). https://doi.org/10.1007/s00105-018-4221-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-018-4221-7

Schlüsselwörter

Keywords

Search

Navigation